SRIH has recently been shown to be effective in reversrng many of the changes observed rn early d~abetlc nephrapathy ION), including k~d n e y hypertrophy and ~ncreascd urinary albumrn excret~on. Although GH is elevated r n IDON, ~t rs unknown whether SRIH exerts it8 protectLve renal effects v~a its ability to suppress GH or v~a other ~n s p~c i f~e c l dtr~.cL rcnill effcctu.
140i12~' 14624%' CAPTOPRIL 1O'N 1Rljl3X' I S O~I~Y . ' CONCLUSIONS: Uoth SRIll and captoprll rncrenle qlo~iicrular PC E, production, and diabetic glornerulr were more scrin~trve Lo SHIll at the lower concentrations tested compared to normal glomerulr lp=0.001 at 10'o~). S~n c e SRIlI appears to have similar clln~cal effects on ON a s captoprll, t l~e above data prov~de p r e l~m~n a r y evldeoce oupport~ng the hypothesin Lhat SRIII may be acting v l e it0 abllrty to alter glomerular PG E, rather than by lowering CH levels a s prevlounly thought. (25 % ) patients o f the NON-GT-group. These r e s u l t s could support r e c e n t findlngs t h a t reduced growth in early life 1 s strongly l l n k e d with impaired g l u c o s e tolerance and appearance o f d i a b e t e s mellitus.
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